Algorae Pharmaceuticals Limited
LVCLF
$0.0063
$0.000916.67%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | 41.30K | 41.20K | -- |
| Total Revenue | -- | -- | 41.30K | 41.20K | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | 41.30K | 41.20K | -- |
| SG&A Expenses | 38.00K | 39.10K | 73.30K | 73.10K | 276.90K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 135.70K | 139.60K | 183.10K | 182.80K | 409.00K |
| Operating Income | -135.70K | -139.60K | -141.90K | -141.60K | -409.00K |
| Income Before Tax | -212.70K | -218.70K | -212.30K | -211.90K | -472.80K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -212.70K | -218.70K | -212.30K | -211.90K | -472.80K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -212.70K | -218.70K | -212.30K | -211.90K | -472.80K |
| EBIT | -135.70K | -139.60K | -141.90K | -141.60K | -409.00K |
| EBITDA | -- | -- | -141.80K | -141.50K | -408.90K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 1.69B | 1.69B | 1.69B | 1.69B | 1.64B |
| Average Diluted Shares Outstanding | 1.69B | 1.69B | 1.69B | 1.69B | 1.64B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |